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K e y  M e s s a g e s 
1. Human papillomavirus (HPV) genotyping, HPV 
type-specific E6/E7 transcript detection, and 
hTERT transcript detection could improve the 
specificity of predicting subsequent development 
of squamous intraepithelial lesions, compared 
with cocktail HPV DNA detection alone.
2. The correlation between HPV RNA and hTERT 
expression supports their interactive role in the 
development of cervical cancer and precursor 
lesions.
3. Prophylactic HPV vaccines, besides protecting 
against cervical cancer, can also reduce the 
Integrated human papillomavirus analysis as an 
adjunct for triage of atypical cervical cytology
Introduction
Cervical cytology screening is effective for 
prevention of cervical cancer by detecting cervical 
cancer and its precursors—squamous intraepithelial 
lesions. The most common abnormal cytological 
finding encountered is atypical squamous cells 
of undetermined significance (ASCUS), which is 
associated with the risk of harbouring cervical cancer 
and its precursors.1 The large number of ASCUS 
cases is a considerable burden for any screening 
programme. 
 High-risk human papillomaviruses (HPV) are 
carcinogens of cervical cancer. For triage of women 
with ASCUS, the Hybrid Capture 2 test (HC2) is 
most widely applied. When the ASCUS samples 
are positive for HPV, the women can be referred 
for colposcopy directly. When the samples are 
negative, women can return to cytology screening. 
This practice enables early referral for colposcopy 
and earlier diagnosis of serious cervical lesions. 
To improve the specificity of the HPV cocktail 
test, HPV genotyping, HPV transcription status, 
and evaluation of telomerase activity are potential 
adjunctive indicators.
 HPV genotyping can be performed by 
polymerase chain reaction (PCR) using type-
specific or consensus primers and sequencing, 
HPV DNA chips, or linear blots.2 In addition, 
SNIPER HPV Genotyping Biochip Assay (previously 
named microarray-in-microwell assay) has been 
developed locally.3 Active HPV infection can be 
detected by assessing RNA transcription of two 
HPV oncogenes—E6 and E7—that interact with two 
important tumour suppressor genes—p53 and RB—
respectively. Among women with ASCUS, HPV 
Hong Kong Med J 2014;20(Suppl 6):S44-7
RFCID project number: 07060562
ANY Cheung *, OG Wong, KKY Chan, MS Yang, CH Tsang, SL Ji, CK Lo, E Szeto, E Wong, HYS Ngan
1 ANY Cheung *, 1 OG Wong, 1 KKY Chan, 2 MS Yang, 2 CH Tsang, 
2 SL Ji, 1 CK Lo, 1 E Szeto, 1 E Wong, 3 HYS Ngan
1  Department of Pathology, The University of Hong Kong, Queen Mary 
Hospital
2 Department of Biology and Chemistry, City University of Hong Kong 
3 Department of Obstetrics and Gynaecology, The University of Hong 
Kong, Queen Mary Hospital
* Principal applicant and corresponding author: anycheun@pathology.hku.hk
RNA transcription may potentially identify high-
grade cervical lesions.4 Telomerase adds telomeric 
DNA repeats onto the ends of the chromosomes 
during cell proliferation. Activation of telomerase 
is important for the sustained proliferation and 
development of tumours. Telomerase activity may 
be useful for cervical cancer screening. hTERT is a 
catalytic protein subunit of the telomerase enzyme 
complex and is a rate-limiting component of 
telomerase activity. These assays may be developed 
as potential adjuncts for cervical cancer screening.
 This study aimed to investigate whether 
one-stop integrated HPV molecular analysis can 
facilitate efficient triage of women with equivocal 
cytology diagnoses, and to enhance understanding 
of HPV genotypes and transcription in relation to 
telomerase activity in the development of cervical 
cancer. 
Methods
This study was conducted from January 2008 to 
December 2009. In a screening population of Hong 
Kong, HPV DNA (HC2)–positive ASCUS was 
tested for HPV genotypes, HPV type-specific RNA 
transcription, and hTERT RNA transcription by 
SNIPER HPV Genotyping Biochip Assay, nested 
PCR, and real-time PCR. Correlation between these 
parameters and outcomes of patients was evaluated. 
 Among 184 419 liquid-based cervical cytology 
samples,1 7286 (4.0%) were diagnosed with ASCUS. 
Of 3618 cases undergoing HPV DNA testing using 
HC2, 1984 (54.8%) were positive for high-risk HPV 
and 1634 (45.2%) were negative. After checking the 
RNA quality of the cytology residues of 871 HC2-
positive ASCUS, 604 cases were used for HPV 
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES
burden of screening for those with atypical 
squamous cells of undetermined significance. 
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genotyping, HPV type-specific and hTERT RNA 
transcription. For hTERT study, 20 normal cytology 
samples, 20 low-grade squamous intraepithelial 
lesions (LSIL), 15 high-grade SILs (HSIL), and 7 
squamous cell carcinomas (SCC) were also included. 
 The subsequent cytological and colposcopic 
biopsy findings of patients with ASCUS were 
retrieved. The findings of LSIL (for cytology) or 
cervical interstitial neoplasia (for colposcopy) or 
above were used as cut offs.
 DNA and RNA were extracted from the cervical 
cytology residues of the 871 samples. The quality 
and quantity were checked. Reverse transcription 
was carried out on extracted RNA using random 
hexamer with SuperScript III Reverse Transcriptase 
(Life Technologies, Carlsbad, CA, USA). HPV 
genotyping was performed for 604 samples using 
the locally developed SNIPER HPV Genotyping 
Biochip Assay.3 PCR amplification was carried out 
using biotin-labelled consensus primers targeting 
for the HPV polymorphic L1 region together with a 
combination pool of HPV-specific primers designed 
to amplify 29 HPV genotypes. Primers targeting beta-
globin served as a DNA positive control. The biotin-
labelled amplicons were hybridised specifically 
to the immobilised oligonucleotide probes on a 
membrane-based biochip when the amplicons 
contained matched sequences of the complementary 
probes. Following hybridisation, signal visualisation 
was achieved through colour complex formation 
with streptavidin peroxidase conjugate. The image 
of each biochip in the microplate was captured by an 
imaging system and analysed automatically. 
 The HPV E6/E7 transcript of various HPV 
subtypes was evaluated by type-specific nested 
PCR.4 Cervical cancer cell lines HeLa, C4-1, SiHa, 
ME180, and C33A were used as positive and 
negative controls. The final products amplified from 
each HPV type-specific nested PCR was separated 
by gel electrophoresis and visualised by ultraviolet-
transillumination after ethidium bromide staining. 
Both E6 and E7 viral oncogenes of HPV are 
transcribed from a common promoter. Full length 
E6/E7 transcript encodes the E6 and E7 proteins, 
whereas the spliced variants E6*I and E6*II encode 
truncated E6 proteins with different roles in the 
virus life cycle in addition to the E7 protein. The 
size of the amplified products therefore reflected 
the expression of the full length E6 or truncated E6 
proteins. The HPV E6/E7 transcript level was also 
measured by quantitative PCR (qPCR) using iQ 
SYBR Green Supermix kits (Bio-Rad Laboratories, 
Hercules, CA, USA), and inner primers of nested 
PCR. The relative level was compared with the ΔΔCt 
method using the threshold cycle for glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) as the 
normalising control.
 The level of hTERT in each sample was 
compared by qPCR using the relative standard 
curve method. Both custom-made TaqMan Gene 
Expression Assay (for Taqman qPCR) targeting exon 
II of hTERT transcript (Life Technologies, Carlsbad, 
CA, USA) and primers targeting the same region 
(for SYBR Green qPCR) were used. The TaqMan 
assay for GAPDH Hs99999905_m1 was used for 
normalisation of the amount of cDNA used in each 
reaction. Full-length cDNA of hTERT and GAPDH 
were serially diluted and included in each plate for 
the construction of standard curves.
 The Chi-squared test (2-tailed) was used to 
determine whether the distribution of individual 
HPV genotype or HPV E6/E7 transcript status 
differed in cases with different follow-up findings. 
Mann-Whitney U test was used to evaluate the 
correlation between the level of hTERT transcript 
and the follow-up findings. Receiver operating 
characteristic curve analysis was used to determine 
the cut-off value of the hTERT mRNA level, above 
which was regarded as ‘positive’. Sensitivities, 
specificities, and positive and negative predictive 
values of these molecular tests were calculated. A P 
value of <0.05 was considered statistically significant. 
FIG.  Human papillomavirus (HPV) genotype HPV58 is identified in a Hybrid Capture 2 test positive sample with atypical 
squamous cells of undetermined significance using the SNIPER HPV Genotyping Biochip Assay. For control, three spots 
indicated as positive (+ve) are for colour development control and image alignment. Human beta-globin (HB) serves as an 
internal control for DNA extraction.
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Results
Women with ASCUS who were positive for HPV 
were more likely to have HSIL (P<0.001, Fisher’s 
exact test) and LSIL or above (P<0.001, Fisher’s exact 
test) detected in follow-up cervical cytology and 
histology samples.
 The HPV genotypes in each ASCUS sample 
were identified by SNIPER HPV Genotyping Biochip 
Assay (Fig). The HPV genotype profiles determined 
by the biochip assay analysis are summarised in 
Table 1. The five most common high-risk HPV 
genotypes detected were HPV52 (21.1%), HPV16 
(15.5%), HPV58 (15.2%), HPV39 (7.6%), and HPV18 
(7.2%). Low-risk HPV genotypes were also detected, 
but mainly as mixed infection. The six most 
common types were HPV6 (16.0%), HPV55 (13.8%), 
HPV44 (12.8%), HPV54 (11.7%), HPV40 (11.7%), 
and HPV11 (10.6%). This concurred with the focus 
of HC2 for detection of high-risk HPV. Presence of 
HPV33 (P=0.001), HPV58 (P=0.024), and HPV68 
(P=0.009) correlated with subsequent development 
of HSIL or above, whereas HPV52 (P=0.025) and 
HPV31 (P=0.049) correlated with development of 
LSIL or above. There was no significant difference in 
outcomes between single or mixed HPV infections. 
 Full length and spliced variants of E6/E7 
transcripts of each HPV genotype could be identified 
by the size of the amplified products. The distribution 
of the HPV E6/E7 transcript is summarised in Table 
2. To evaluate the significance of HPV oncogenic E6/
E7 transcript load, the level of type-specific E6/E7 
transcripts was correlated with cytology and biopsy 
follow-up data. Nested PCR HPV transcription 
study showed that HPV58 (P=0.023) and HPV59 
(P=0.026) mRNA transcripts correlated with 
subsequent detection of LSIL or above. Correlation 
between HPV58 mRNA transcripts (P=0.043) and 
development of HSIL or above was demonstrated by 
real time PCR.
 The hTERT mRNA level significantly increased 
in each lesion grade (P=0.0129, one-way ANOVA; 
P=0.0014, test for linear trend). The increase was 
significant between normal samples and LSIL 
(P=0.0327), HSIL (P=0.0026), and SCC (P=0.0064), 
as well as between ASCUS and HSIL (P=0.0401) and 
SCC (P=0.0319). Among the 600 cases of ASCUS 
positive for high-risk HPV, the difference was not 
significant between cases of ASCUS with or without 
LSIL or above (P=0.696). hTERT/GAPDH level in 
specific HPV subtype–infected cases was further 
analysed. In HPV33-infected cases, the hTERT level 
was significantly higher in cases with a worse follow-
up (LSIL or above) [P=0.017]. Among HPV58- 
(P=0.011), HPV33- (P=0.031), and HPV39- (P=0.045) 
infected cases, hTERT transcripts correlated with 
subsequent detection of HSIL or above.
 The correlation between E6/E7 mRNA of 
each HPV genotype and hTERT/GAPDH was 
conducted using Spearman rho test. Correlation 
was noted in HPV16- (r=0.486, P<0.000), HPV18- 
(r=0.557, P<0.000), HPV52- (r=0.704, P<0.000), 
HPV58- (r=0.451, P=0.003), and HPV33- (r=0.529, 
P<0.035) infected cases. This indicated that some 
HPV subtypes may be more capable of inducing 
oncogenic changes such as telomerase activation.
 The sensitivity, specificity, and positive and 
negative predictive values of HC2 for detecting HSIL 
or above in this cohort of 3618 cases of ASCUS was 
94.3%, 47.6%, 10%, and 99.3%, respectively. Among 
the HC2-positive ASCUS cases, the specificity and 
positive predictive value respectively increased to 
82.3% and 21.82% after HPV58 genotyping, and to 
TABLE 1.  Human papillomavirus (HPV) genotypes found in 604 
successfully genotyped samples with atypical squamous cells of 
undetermined significance
HPV genotype No. (%) of 
samples with 
HPV types 
detected
% of total 
identifiable 
HPV genotypes
High risk 
HPV16 112 (15.5) 13.6
HPV18 52 (7.2) 6.3
HPV26 2 (0.3) 0.2
HPV31 23 (3.2) 2.8
HPV33 36 (5.0) 4.4
HPV35 11 (1.5) 1.3
HPV39 55 (7.6) 6.7
HPV45 9 (1.3) 1.1
HPV51 49 (6.8) 5.9
HPV52 152 (21.1) 18.4
HPV53 13 (1.8) 1.6
HPV56 19 (2.6) 2.3
HPV58 110 (15.2) 13.3
HPV59 19 (2.6) 2.3
HPV66 14 (1.9) 1.7
HPV68 38 (5.3) 4.6
82 (MM4) 8 (1.1) 1.0
Subtotal 722 (100) 87.5
Low risk
HPV6 15 (16.0)* 1.8
HPV11 10 (10.6)* 1.2
HPV40 11 (11.7)* 1.3
HPV42 6 (6.4)* 0.7
HPV43 9 (9.6)* 1.1
HPV44 12 (12.8)* 1.5
HPV46 1 (1.1)* 0.1
HPV54 11 (11.7)* 1.3
HPV55 13 (13.8)* 1.6
HPV73 6 (6.4) 0.7
Subtotal 94 (100) 11.3
Indeterminate and other
HPV67 9 (100) 1.1
Total 825 100
* Mixed infection
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93% and 22.7% after assessment of HPV58 RNA 
transcript. The corresponding values were 66.0% 
and 13.4% when hTERT RNA assay alone was used, 
and 62.8% and 20.0% for hTERT RNA evaluation in 
HPV58-infected cases.
Discussion
In this study, the five most common high-risk 
HPV genotypes detected, in decreasing order, were 
HPV52, HPV16, HPV58, HPV39, and HPV18. These 
accounted for two-thirds of the HPV genotypes 
detected. Among ASCUS in this local population, 
HPV52 and HPV58 were more common than HPV16 
and HPV18, with high prevalence in both cervical 
cancers and precancerous lesions.5 The distribution 
of HPV genotypes in different populations varies. 
This may be due to differences in hospital versus 
screening populations and the methodology used for 
HPV genotyping. 
 About one-quarter of ASCUS in our screening 
population were HPV negative and did not need 
colposcopy if HPV vaccine was administered. This 
may lessen the burden on the screening programme. 
In addition, HPV33, HPV58, and HPV68 correlated 
with subsequent detection of HSIL or above, 
whereas HPV52 correlated with development of 
LSIL or above. In most studies, HPV16 and/or 
HPV18 carry prognostic significance. The difference 
in findings related to disease outcome may be due to 
the dominant prevalence of HPV58 and HPV52 in 
this population with ASCUS.
 When HPV type–specific RNA transcript 
status correlated with subsequent follow-up using 
nested PCR, HPV58 E6/E7 transcription correlated 
with subsequent development of more serious 
cervical lesions. Both HPV58 detection and E6/E7 
transcription were prominent among the high-risk 
HPV genotypes. 
 hTERT transcription levels did not correlate 
with subsequent detection of serious cervical lesions. 
Nonetheless, subsequent development of cervical 
lesions in HPV16- and HPV58-infected cases were 
noted. 
 Detection of high-risk HPV by cocktail HC2 
achieved a high sensitivity and negative predictive 
value but moderate specificity and positive predictive 
value. Additional HPV58 genotyping and RNA 
transcript assay as well as hTERT assay in HPV58-
infected cases enhanced the specificity and positive 
predictive values. These findings support the use of 
these adjunct techniques to cytology and HPV DNA 
testing in triaging women with ASCUS. 
 Transcription of hTERT correlated with that of 
HPV16, HPV18, HPV52, HPV58, and HPV33. This 
suggested significant interaction between HPV and 
telomerase activity. These HPV genotypes may be 
more capable of inducing oncogenic changes including 
telomerase activation. Indeed, HPV oncogenic 
protein E6 is reported to induce the transcription of 
hTERT and influence telomerase activity leading to 
cell immortalisation and cervical carcinogenesis. 
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